Human papillomavirus type 39 L1 protein (HPV-39 L1)

Human papillomavirus type 39 (HPV-39) L1 protein is the primary structural component of the virus's icosahedral capsid, playing a fundamental role in viral transmission and pathogenesis [2, 16]. As the major capsid protein, L1 self-assembles into pentameric units called capsomeres, which further organize into 72 pentamers to form non-infectious virus-like particles (VLPs) that are highly immunogenic [5, 9]. HPV-39 is classified as a high-risk oncogenic type, primarily associated with persistent mucosal infections that can progress to cervical intraepithelial neoplasia and invasive cervical cancer [4, 7]. The L1 protein is essential for the initial stages of infection, mediating viral attachment to host cell surface receptors, such as heparan sulfate proteoglycans, before internalization via endocytosis [1, 15]. While current mainstream prophylactic vaccines like Gardasil 9 do not include HPV-39 L1, this protein is a key target for next-generation multivalent investigational vaccines such as the 14-valent candidate SCT1000 [1, 5]. These vaccines function by inducing the production of neutralizing antibodies that target surface-exposed epitopes on the L1 protein to block viral entry [10, 14]. Furthermore, L1 expression in cervical cytology serves as a diagnostic biomarker, as its absence often indicates the transition from a productive viral infection to a transformative neoplastic state [1, 11].

Other names

Major capsid protein L1HPV39 L1Human papillomavirus 39 L1 proteinHPV-39 Major capsid protein L1

Stimulation of the immune system to produce type-specific neutralizing antibodies that bind to the L1 capsid protein, thereby preventing viral attachment and internalization into host epithelial cells.